CY1108457T1 - Παραγωγα ξανθινης ως ανταγωνισται υποδοχεως α2β αδενοσινης - Google Patents

Παραγωγα ξανθινης ως ανταγωνισται υποδοχεως α2β αδενοσινης

Info

Publication number
CY1108457T1
CY1108457T1 CY20081101212T CY081101212T CY1108457T1 CY 1108457 T1 CY1108457 T1 CY 1108457T1 CY 20081101212 T CY20081101212 T CY 20081101212T CY 081101212 T CY081101212 T CY 081101212T CY 1108457 T1 CY1108457 T1 CY 1108457T1
Authority
CY
Cyprus
Prior art keywords
xanthinis
adenosin
competed
receptor
production
Prior art date
Application number
CY20081101212T
Other languages
English (en)
Inventor
Rao Kalla
Thao Perry
Elfatih Elzein
Vaibhav Varkhedkar
Xiaofeng Li
Prabha Ibrahim
Venkata Palle
Dengming Xiao
Jeff Zablocki
Original Assignee
Cv Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics, Inc. filed Critical Cv Therapeutics, Inc.
Publication of CY1108457T1 publication Critical patent/CY1108457T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Αποκαλύπτονται ενώσεις οι οποίες είναι ανταγωνισταí υποδοχέως Α2Β αδενοσίνης, χρήσιμοι δια νοσηλείαν διαφόρων νοσηρών καταστάσεων, συμπεριλαμβανομένου άσθματος και διάρροιας.
CY20081101212T 2003-05-06 2008-10-27 Παραγωγα ξανθινης ως ανταγωνισται υποδοχεως α2β αδενοσινης CY1108457T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2003/014085 WO2004106337A1 (en) 2003-05-06 2003-05-06 Xanthine derivatives as a2b adenosine receptor antagonists
EP03817096A EP1622908B1 (en) 2003-05-06 2003-05-06 Xanthine derivatives as a2b adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
CY1108457T1 true CY1108457T1 (el) 2014-04-09

Family

ID=33488737

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101212T CY1108457T1 (el) 2003-05-06 2008-10-27 Παραγωγα ξανθινης ως ανταγωνισται υποδοχεως α2β αδενοσινης

Country Status (16)

Country Link
EP (1) EP1622908B1 (el)
JP (1) JP2006515316A (el)
CN (1) CN100590125C (el)
AT (1) ATE403656T1 (el)
AU (1) AU2003249604B2 (el)
CA (1) CA2524778C (el)
CY (1) CY1108457T1 (el)
DE (1) DE60322748D1 (el)
DK (1) DK1622908T3 (el)
ES (1) ES2311759T3 (el)
HK (1) HK1092137A1 (el)
MX (1) MXPA05011860A (el)
NZ (1) NZ543416A (el)
PT (1) PT1622908E (el)
SI (1) SI1622908T1 (el)
WO (1) WO2004106337A1 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2301937A1 (en) * 2005-06-16 2011-03-30 Cv Therapeutics, Inc. Prodrugs of A2b adenosine receptor antagonists
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
EP1989210A2 (en) * 2006-03-02 2008-11-12 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
WO2009088518A1 (en) * 2008-01-11 2009-07-16 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for the treatment of cancer
US8871751B2 (en) 2008-01-18 2014-10-28 The Board Of Trustees Of The University Of Illinois Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer
AU2009230679B2 (en) * 2008-03-26 2013-07-18 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist
WO2009157938A1 (en) * 2008-06-26 2009-12-30 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for treating cancer
EP2405917B1 (en) * 2009-03-13 2014-04-23 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
JP5843778B2 (ja) 2009-11-09 2016-01-13 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物、その調製およびその使用
AU2011303420B2 (en) 2010-09-13 2014-03-20 Impetis Biosciences Ltd. Purine compounds as prodrugs of A2B adenosine receptor antagonists, their process and medicinal applications
NZ711718A (en) * 2013-03-15 2020-05-29 Hydra Biosciences Llc Substituted xanthines and methods of use thereof
ES2580702B1 (es) 2015-02-25 2017-06-08 Palobiofarma, S.L. Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina
WO2017106352A1 (en) 2015-12-14 2017-06-22 Raze Therapeutics, Inc. Caffeine inhibitors of mthfd2 and uses thereof
US11045472B2 (en) * 2017-05-05 2021-06-29 Arcus Biosciences, Inc. Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
CN112218867B (zh) * 2018-03-05 2023-11-21 泰昂治疗公司 腺苷受体拮抗剂及其用途
MX2021008094A (es) 2019-01-11 2021-09-21 Omeros Corp Metodos y composiciones para el tratamiento del cancer.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
DE8817122U1 (el) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 6507 Ingelheim, De
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
WO1995011681A1 (en) * 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
DE19535504A1 (de) * 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
DK0956855T3 (da) * 1998-04-24 2003-07-14 Leuven K U Res & Dev Immunhæmmende effekter af 8-substituerede xanthin-derivater
US6545002B1 (en) * 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
DE60206756T2 (de) * 2001-06-29 2006-07-13 CV Therapeutics, Inc., Palo Alto Purin derivate als a2b adenosin rezeptor antagonisten
PL370207A1 (en) * 2001-11-09 2005-05-16 Cv Therapeutics, Inc. A2b adenosine receptor antagonists
NZ528591A (en) * 2002-02-01 2006-11-30 King Pharmaceuticals Res & Dev 8-heteroaryl xanthine adenosine A2B receptor antagonists and their pharmaceutical use

Also Published As

Publication number Publication date
ATE403656T1 (de) 2008-08-15
CN100590125C (zh) 2010-02-17
NZ543416A (en) 2009-01-31
EP1622908A1 (en) 2006-02-08
DE60322748D1 (de) 2008-09-18
HK1092137A1 (en) 2007-02-02
CN1771250A (zh) 2006-05-10
ES2311759T3 (es) 2009-02-16
DK1622908T3 (da) 2008-11-17
AU2003249604A1 (en) 2005-01-21
CA2524778C (en) 2013-01-29
PT1622908E (pt) 2008-11-14
AU2003249604B2 (en) 2011-06-30
MXPA05011860A (es) 2006-02-17
EP1622908B1 (en) 2008-08-06
SI1622908T1 (sl) 2008-12-31
JP2006515316A (ja) 2006-05-25
WO2004106337A1 (en) 2004-12-09
CA2524778A1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
CY1108457T1 (el) Παραγωγα ξανθινης ως ανταγωνισται υποδοχεως α2β αδενοσινης
ATE461932T1 (de) Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
SMP200600024B (it) 2,6-Biseteroaril-4-amminopirimidine come antagonisti del recettore dell'adenosina
RS20050306A (en) Purine compounds and uses thereof as cannabinoid receptor ligands
CR7728A (es) Nuevas quinazolinas espirocondensadas y su uso como inhibidores de la fosfodiesterasa
ATE538123T1 (de) 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors
ATE541857T1 (de) Optimierte fc-varianten und herstellungsverfahren dafür
IL178365A (en) Selective antagonists of a2a adenosine receptors
WO2003106654A3 (en) XYLANASES, NUCLEIC ACIDS ENCODING THEM, AND METHODS OF MAKING AND USING THE SAME
NL1026776A1 (nl) Antilichamen tegen c-MET.
IS7945A (is) 4,5-díarýlþíasólafleiður sem CB-1 tenglar
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
NO20061952L (no) Pyrimidin-2-aminderivater og deres anvendelse som A2B-adenosinreseptorantagonister
MEP15908A (en) 1-amino-2-oxy-substituted tetrahydronaphtalene derivatives, methods for the production thereof, and their use as antiphlogistics
CY1107875T1 (el) Παραγωγα αμινοκινολινης και η χρηση τους ως συνδετες των α3 αδενοσινης
ATE432282T1 (de) 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten
ATE418555T1 (de) A2a-adenosinrezeptorantagonisten
IL182528A0 (en) Purine derivatives for use as adenosin a-2a receptor antagonists
EA200702071A1 (ru) Новые соединения
TW200714603A (en) Acylaminobicyclic heteroaromatic compounds and uses thereof
EA200701592A1 (ru) Композиты и способы их получения и использования
DE602007012313D1 (de) Als a2b-adenosinrezeptorantagonisten geeignete 5-phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4,5-büpyridin-2-onderivate
EA200900010A1 (ru) Замещенные 8-[6-амино-3-пиридил]ксантины
EA200500005A1 (ru) Способ лечения повреждения, вызванного реперфузией после ишемии, с использованием антагонистов рецептора аденозина
AR056279A1 (es) Derivados de aril 1,4- pirazina sustituidos, composicion farmaceutica y un metodo in vitro